Loading…
← CockpitCompetitor Analysis › 600645.SS Vcanbio Cell & Gene Engineering Corp., Ltd. Class AOpen in the cockpit ↗

Vcanbio Cell & Gene Engineering Corp., Ltd. Class A600645.SSCompetitor analysis, valuation and peers

China · CNY·Industrials›Miscellaneous Commercial Services

Chinese cell and gene engineering company involved in cord-blood banking and cell-therapy services.

≈ A China-based cord-blood bank/cell-therapy companyMomentum weak 39
Mkt cap
$1.11B
US dollars, full cap
Free float
73%
of shares outstanding
$/day
$19.8M
20-day average traded
Fwd P/E
40.7×
forward earnings
ROIC−WACC
+2.9 pp
WACC 6.8%
Hurdle
+7 pp
Req g minus delivered
Next earnings
156 days
23 Apr 2027
Close · CNYCN¥16.09
1D-0.7%
1W-9.0%
1M-8.9%
3M-20.7%
6M-29.1%
YTD-36.1%
1Y-35.3%
ATR %4.0%
52w lowhigh51.2% off high

What Vcanbio Cell & Gene Engineering does

Chinese cell and gene engineering company involved in cord-blood banking and cell-therapy services.

Families pay an up-front processing fee, then yearly storage fees to keep cord blood frozen for possible future treatment, so income builds with the number of samples stored. Cell-therapy services extend the business beyond storage.

In one line: A China-based cord-blood bank/cell-therapy company.

Products and services

  • Cord-blood banking
  • Cell-therapy services

Customers

  • Expectant families
  • Hospitals/clinics

Where it sits in the supply chain

  • Biotech services
  • Cord-blood/stem-cell banking
  • Cell and gene therapy services

What could go right

  • Rising interest in stem-cell banking and cell therapy in China

What could go wrong

  • Regulatory scrutiny of biobanking/cell therapy

Moat: narrow (regulatory licence, installed base). Cord-blood banking requires regional licences that limit new entrants.

Headquarters: Tianjin, China · Employees: 1,935

Vcanbio Cell & Gene Engineering at a glance

Size Vcanbio Cell & Gene Engineering (600645.SS) is a China Industrials company (Miscellaneous Commercial Services) with a market value of $1.11B, the 1956th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥16.09 on 18 Nov 2026.

Performance Over six months the shares fell 29.1%, against -13.9% for the median peer and -20.0% for the China market (cap-weighted) — 6th lowest of 21 in its peer set.

Growth Revenue fell 6.3% over the last twelve months (peer median +8.6%); the operating margin is 11.7% (peer median 10.9%).

Valuation It trades at 40.7× forward earnings against a peer median of 16.7× (3rd most expensive of 18).

Price implies For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is +7 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 2.9 points above its cost of capital (6.8% WACC).

Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).

Relative performance

70809010021 May 202621 Aug 202618 Nov 2026Peer median 88600645.SS 72
Six months, rebased to 100: Vcanbio Cell & Gene Engineering against the median of its 20 peers (local-currency closes).

Vcanbio Cell & Gene Engineering financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.38BCN¥1.44BCN¥1.57BCN¥1.58BCN¥1.55B
Revenue growth—-8%-1%+2%—
Gross profitCN¥1.03BCN¥912MCN¥984MCN¥1.00BCN¥959M
EBITDAn/aCN¥305MCN¥317MCN¥298MCN¥296M
Net incomeCN¥113MCN¥114MCN¥100MCN¥106MCN¥113M
Free cash flowCN¥261MCN¥276MCN¥218MCN¥210MCN¥163M
Capital expenditureCN¥41.4MCN¥49.6MCN¥67.3MCN¥88.6MCN¥99.2M
Total debtCN¥64.7MCN¥68.8MCN¥112MCN¥126MCN¥130M

Quarterly statements and history in the cockpit →

Vcanbio Cell & Gene Engineering competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%-20%0%600861688137WLDN0667CASHRHLD6883921515BMAG603112688112NRO131970SSM688522300938SIQGLOCONCORDBIO600645.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Vcanbio Cell & Gene Engineering is the large dot.

Fundamentals: revenue growth against valuation

-50%-25%0%+25%20×40×600861WLDN0667688252CASH688392BMAG688112NRO131970SSM688522300938GLOCONCORDBIO600645.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Vcanbio Cell & Gene Engineering is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%WLDN0667688252CASH603112688112NROSSMSIQGLOCONCORDBIO600645.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Vcanbio Cell & Gene Engineering is the large dot.

Vcanbio Cell & Gene Engineering competitors and peer comparison

How Vcanbio Cell & Gene Engineering compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Vcanbio Cell & Gene Engineering against its 20 peers (data as of 18 Nov 2026)
Measure600645.SSPeer medianRank in peer set
1-month return-8.9%-7.9%10th lowest of 21
6-month return-29.1%-13.9%6th lowest of 21
Distance from 52-week high-51.2%-37.5%6th lowest of 21
Revenue growth (TTM)-6.3%+8.6%2nd lowest of 21
Operating margin11.7%10.9%9th highest of 21
Forward P/E40.7×16.7×3rd most expensive of 18
Growth the price implies (Req g, 7 yrs)8.9%7.7%7th least demanding of 13
Growth delivered (Del g)+1.9%+11.8%lowest of 12
Hurdle (Req g minus delivered)+7.0 pp-11.6 pp2nd most demanding of 12
ROIC minus cost of capital+2.9 pp-0.0 pp10th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Vcanbio Cell & Gene Engineering 600645.SSChina$1.11B-29%-6%12%40.7×8.9%+1.9%
FESCO 600861.SSChina$1.10B-15%+4%1%10.5×n/an/a
Suzhou Novoprotein Scientific 688137.SSChina$1.12B+117%+8%-62%n/an/an/a
Willdan WLDNUnited States$1.13B-20%+19%7%14.6×17.2%+11.8%
China East Education 0667.HKHong Kong$1.09B-21%+16%22%7.8×-7.5%+4.1%
Jadard Technology 688252.SSChina$1.14B-22%+6%12%22.3×12.0%+31.3%
Prosegur Cash CASH.MCSpain$1.07B+10%-2%11%9.6×-12.1%+5.7%
Resolute Holdings Management RHLDUnited States$1.16B+34%+10%12%n/a16.6%n/a
SBT Ultrasonic Technology 688392.SSChina$1.06B-36%+42%17%49.3×n/an/a
Nittetsu Mining 1515.TJapan$1.17B-3%+18%8%n/an/an/a
Bajaj Mobility BMAG.SWSwitzerland$1.05B+40%-47%-44%8.9×n/an/a
Shanxi Huaxiang 603112.SSChina$1.19B-33%+9%11%11.6×0.9%+16.2%
Siglent Technologies 688112.SSChina$1.19B-26%+30%24%39.2×27.7%+22.0%
Neurones NRO.PAFrance$1.03B+3%+7%9%16.9×-7.9%+10.3%
DOOSAN TESNA 131970.KSSouth Korea$1.03B-62%+5%10%43.1×n/an/a
Service Stream SSM.AXAustralia$1.03B-9%+1%3%16.7×13.9%+24.0%
Naruida Technology 688522.SSChina$1.01B-32%+20%14%19.6×n/an/a
EMTEK (Shenzhen) 300938.SZChina$1,000M-54%+11%27%28.5×n/an/a
Smartgroup SIQ.AXAustralia$986M-6%+10%37%14.7×-1.3%+8.8%
GL events GLO.PAFrance$986M-13%+6%10%8.8×3.4%+29.1%
Concord Biotech CONCORDBIO.NSIndia$1.26B-2%+4%28%33.9×44.4%+11.6%

Questions

Which companies are Vcanbio Cell & Gene Engineering's closest peers?
The cockpit's peer set: FESCO (600861.SS), Suzhou Novoprotein Scientific (688137.SS), Willdan (WLDN), China East Education (0667.HK), Jadard Technology (688252.SS), Prosegur Cash (CASH.MC), Resolute Holdings Management (RHLD), SBT Ultrasonic Technology (688392.SS).
Is Vcanbio Cell & Gene Engineering expensive compared with its peers?
On forward p/e it trades at 40.7× against a peer median of 16.7×, 3rd most expensive of 18 in its peer set. For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is +7 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Vcanbio Cell & Gene Engineering stock performed?
Over six months to 18 Nov 2026 the shares returned -29.1% against -13.9% for the median peer; over one year -35.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.